{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:32:43Z","timestamp":1793219563098,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.therap.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:37:24Z","timestamp":1775666244000},"page":"386-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclin-dependent kinase inhibitors and kidney injury: Analysis of the French pharmacovigilance database"],"prefix":"10.1016","volume":"81","author":[{"given":"Laurence","family":"Lagarce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Gaiffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Freppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Storck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-5998","authenticated-orcid":false,"given":"Marie","family":"Briet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.03.005_bib0155","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.therap.2026.03.005_bib0160","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2026.03.005_bib0165","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.therap.2026.03.005_bib0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2026.03.005_bib0175","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/imj.14629","article-title":"Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer","volume":"49","author":"Wilson","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.therap.2026.03.005_bib0180","series-title":"Highlights of prescribing information, Ibrance(R) (Palbociclib)","year":"2019"},{"key":"10.1016\/j.therap.2026.03.005_bib0185","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1073\/pnas.1424313112","article-title":"Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions","volume":"112","author":"Pabla","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.therap.2026.03.005_bib0190","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2\u2212 metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.therap.2026.03.005_bib0195","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2026.03.005_bib0200","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2026.03.005_bib0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.therap.2026.03.005_bib0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.therap.2026.03.005_bib0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/23993693211021420","article-title":"An elevated serum creatinine in a patient receiving palbociclib","volume":"5","author":"Bonilla","year":"2021","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0220","doi-asserted-by":"crossref","DOI":"10.1177\/20543581221106246","article-title":"Targeted cancer therapies causing elevations in serum creatinine through tubular secretion inhibition: a case report and review of the literature","volume":"9","author":"Mach","year":"2022","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.therap.2026.03.005_bib0225","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/23993693221085285","article-title":"Ribociclib-induced pseudo-acute kidney injury","volume":"6","author":"Sy-Go","year":"2022","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0230","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1177\/10781552211007202","article-title":"Ribociclib induced acute kidney injury: a case report","volume":"27","author":"Gulturk","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.therap.2026.03.005_bib0235","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/tbj.13980","article-title":"Abemaciclib-induced reversible grade 4 nephrotoxicity","volume":"26","author":"Da Silva","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.therap.2026.03.005_bib0240","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","article-title":"Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors","volume":"7","author":"Gupta","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.therap.2026.03.005_bib0245","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/23993693241256700","article-title":"A case of biopsy proven acute tubular injury from cyclin dependent kinase 4\/6 inhibitor","volume":"8","author":"Gwinn","year":"2024","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0250","doi-asserted-by":"crossref","first-page":"1389562","DOI":"10.3389\/fneph.2024.1389562","article-title":"Case report: a case of pseudo-acute kidney injury due to cyclin-dependent kinase inhibitor","volume":"4","author":"Errabelli","year":"2024","journal-title":"Front Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/23993693241232733","article-title":"Palbociclib-associated nephrotoxicity in a patient with breast cancer","volume":"8","author":"Tang","year":"2024","journal-title":"J Onco-Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12882-025-04442-3","article-title":"Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review","volume":"26","author":"Kumano","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.therap.2026.03.005_bib0265","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1172\/JCI125519","article-title":"FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury","volume":"129","author":"Chang-Panesso","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.therap.2026.03.005_bib0270","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nm.2144","article-title":"Epithelial cell cycle arrest in G2\/M mediates kidney fibrosis after injury","volume":"16","author":"Yang","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.therap.2026.03.005_bib0275","doi-asserted-by":"crossref","first-page":"F379","DOI":"10.1152\/ajprenal.00475.2013","article-title":"CDK4\/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury","volume":"306","author":"DiRocco","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.therap.2026.03.005_bib0280","doi-asserted-by":"crossref","first-page":"113939","DOI":"10.1016\/j.bcp.2020.113939","article-title":"Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms","volume":"177","author":"Kim","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2026.03.005_bib0285","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.therap.2026.03.005_bib0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","article-title":"Immunomodulation by anticancer cell cycle inhibitors","volume":"20","author":"Petroni","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.therap.2026.03.005_bib0295","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.jhepr.2024.101098","article-title":"CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment","volume":"6","author":"Meunier","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.therap.2026.03.005_bib0300","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/1120009X.2024.2433368","article-title":"Ribociclib-induced autoimmune-like hepatitis: a case report","volume":"37","author":"Kavgaci","year":"2025","journal-title":"J Chemother"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:27Z","timestamp":1793217027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0040595726000521"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.005","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclin-dependent kinase inhibitors and kidney injury: Analysis of the French pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}